SEC Form 4 · accession 0001209191-17-027905

Forte Biosciences, Inc. · FBRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 19, 2017

Accepted (ET)

Apr 21, 2017 · 5:34 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001419041

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Apr 19, 2017	C	23,464	—	A	23,464	D
Common Stock^F1	Apr 19, 2017	C	4,117	—	A	4,117	I	By NFS/FMTC FBO Paul Schimmel Rollover IRA
Common Stock^F1	Apr 19, 2017	C	3,623	—	A	3,623	I	By Paul Schimmel Prototype PSP Paul R. Schimmel, TTEE U/A dtd 01/01/1999 FBO Paul Schimmel
Common Stock^F1	Apr 19, 2017	C	3,623	—	A	3,623	I	By Schimmel Revocable Trust Paul R. Schimmel, Trustee Cleo Schimmel, Trustee U/A dtd 9/6/2000
Common Stock	Apr 19, 2017	P	10,000	$10.00	A	13,623	I	By Schimmel Revocable Trust Paul R. Schimmel, Trustee Cleo Schimmel, Trustee U/A dtd 9/6/2000

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series H Preferred Stock^F1	—	Apr 19, 2017	C	161,906	D	—	—	Common Stock	23,464	D
Series F Preferred Stock^F1	—	Apr 19, 2017	C	28,410	D	—	—	Common Stock	4,117	I
Series G Preferred Stock^F1	—	Apr 19, 2017	C	25,000	D	—	—	Common Stock	3,623	I
Series G Preferred Stock^F1	—	Apr 19, 2017	C	25,000	D	—	—	Common Stock	3,623	I

F1Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date.
F2The shares were purchased at the Issuer's initial public offering.